Literature DB >> 14982143

Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs.

G Brébion1, R A Bressan, X Amador, D Malaspina, J M Gorman.   

Abstract

BACKGROUND: We wished to assess the effect of three types of medication on verbal memory impairments in schizophrenia.
METHOD: Forty-eight patients with schizophrenia and 40 healthy control subjects underwent a battery of verbal memory tasks, including free recall, recognition and short-term memory span. All the patients were on antipsychotic medication. In addition, 24 were taking anticholinergic drugs (benztropine) and 30 were taking benzodiazepines. A subsample of 39 had clinical ratings for depressive symptoms. Regression analyses were conducted on the memory measures in this subsample, with negative symptoms, depression, type of antipsychotic medication (conventional v. atypical), benzodiazepines and anticholinergic drugs as predictors.
RESULTS: Type of antipsychotic medication made no significant contribution to memory deficits and benzodiazepine use made very little contribution. However, anticholinergic medication was a predictor of memory impairment, especially with regard to semantic organization. Complementary analyses revealed that patients taking any type of drug with anticholinergic activity (benztropine and/or antipsychotic agents) were significantly impaired relative to the other patients on measures reflecting free recall efficiency and semantic organization.
CONCLUSIONS: Drugs with anticholinergic activity are the major pharmacological agents that contribute to the verbal memory deficit observed in patients with schizophrenia. These drugs appear to act by impeding semantic organization at encoding.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982143     DOI: 10.1017/s0033291703008900

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  12 in total

1.  Subcortical association with memory performance in schizophrenia: a structural magnetic resonance imaging study.

Authors:  Daisuke Koshiyama; Masaki Fukunaga; Naohiro Okada; Fumio Yamashita; Hidenaga Yamamori; Yuka Yasuda; Michiko Fujimoto; Kazutaka Ohi; Haruo Fujino; Yoshiyuki Watanabe; Kiyoto Kasai; Ryota Hashimoto
Journal:  Transl Psychiatry       Date:  2018-01-10       Impact factor: 6.222

Review 2.  Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function.

Authors:  William S Stone; Larry J Seidman
Journal:  Schizophr Bull       Date:  2007-05-15       Impact factor: 9.306

3.  Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users.

Authors:  François Montastruc; Anne Bénard-Laribière; Pernelle Noize; Elodie Pambrun; Fabienne Diaz-Bazin; Marie Tournier; Bernard Bégaud; Antoine Pariente
Journal:  Eur J Clin Pharmacol       Date:  2018-01-06       Impact factor: 2.953

Review 4.  The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes.

Authors:  Raquel E Gur; Monica E Calkins; Ruben C Gur; William P Horan; Keith H Nuechterlein; Larry J Seidman; William S Stone
Journal:  Schizophr Bull       Date:  2006-11-13       Impact factor: 9.306

5.  Cognitive burden of anticholinergic medications in psychotic disorders.

Authors:  Seenae Eum; S Kristian Hill; Leah H Rubin; Ryan M Carnahan; James L Reilly; Elena I Ivleva; Sarah K Keedy; Carol A Tamminga; Godfrey D Pearlson; Brett A Clementz; Elliot S Gershon; Matcheri S Keshavan; Richard S E Keefe; John A Sweeney; Jeffrey R Bishop
Journal:  Schizophr Res       Date:  2017-04-06       Impact factor: 4.939

6.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

7.  Detailed cognitive function and use of drugs with anticholinergic properties in older people: a community-based cross-sectional study.

Authors:  Juho Uusvaara; Kaisu H Pitkala; Hannu Kautiainen; Reijo S Tilvis; Timo E Strandberg
Journal:  Drugs Aging       Date:  2013-03       Impact factor: 3.923

8.  A computational language approach to modeling prose recall in schizophrenia.

Authors:  Mark Rosenstein; Catherine Diaz-Asper; Peter W Foltz; Brita Elvevåg
Journal:  Cortex       Date:  2014-02-08       Impact factor: 4.027

Review 9.  Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

Authors:  Joshua A Berman; David A Talmage; Lorna W Role
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

10.  Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders.

Authors:  Seenae Eum; S Kristian Hill; Ney Alliey-Rodriguez; James M Stevenson; Leah H Rubin; Adam M Lee; Lauren J Mills; James L Reilly; Rebekka Lencer; Sarah K Keedy; Elena Ivleva; Richard S E Keefe; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop
Journal:  Neuropsychopharmacology       Date:  2021-06-18       Impact factor: 8.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.